Browse by author
Lookup NU author(s): Professor Ruth Plummer
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The understanding of the biology of the DNA damage response pathways has increased over recent years and has allowed the development of a number of classes of agents which target elements of the pathways. Clinical development of these has either been as active single agents in molecularly selected tumours or to overcome resistance to existing DNA damaging agents. MGMT inhibitors, PARP inhibitors and APE-1 inhibitors have entered the clinic, with the former blocking Direct Repair and the latter two classes of agent blocking DNA single strand break repair. ATR (Ataxia Telangiectasia and Rad 3 related) kinase is involved in the signalling of DNA double strand breaks, which are potent cytotoxic lesions. Inhibition of ATR in preclinical models enhances the cytotoxicity of ionising radiation and a number of commonly used chemotherapeutic agents. The first ATR inhibitors are entering early clinical trials and this lecture will review the preclinical data and rationale for trial design.
Author(s): Plummer ER
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: 11th International Congress on Targeted Anticancer Therapies (TAT 2013)
Year of Conference: 2013
Pages: 12-12
ISSN: 0923-7534
Publisher: Oxford University Press
URL: http://dx.doi.org/10.1093/annonc/mdt042.25
DOI: 10.1093/annonc/mdt042.25
Library holdings: Search Newcastle University Library for this item
Series Title: Annals of Oncology
ISBN:
